Skip to main content
. Author manuscript; available in PMC: 2022 Jan 17.
Published in final edited form as: Leukemia. 2021 Feb 23;35(5):1279–1290. doi: 10.1038/s41375-021-01177-6

Fig. 3. Survival and cumulative incidence of events from post-induction treatment assignment by treatment arm.

Fig. 3

There is no significant difference in EFS (A) or OS (B) for all KMT2A-r patients assigned to Arm B vs. Arm C-DL2. Similarly, there is no significant difference in EFS for IR patients (C) or HR patients (D) between those assigned to Arm B vs. Arm C-DL2. Cumulative incidences of treatment failure/relapse (E) and death as a first event (F) are also not different between Arm B and Arm C-DL2.